Mineralys Therapeutics (MLYS) Accounts Payables (2022 - 2026)
Mineralys Therapeutics (MLYS) posted Accounts Payables of $1.1 million for Q1 2026, down 44.67% sequentially from $2.0 million in Q4 2025, and up 199.2% YoY from $373000.0 in Q1 2025.
Mineralys Therapeutics (MLYS) Accounts Payables (2022 - 2026) Analysis & Trends
Mineralys Therapeutics has reported Accounts Payables for 5 years, with the latest figure at $1.1 million in Q1 2026.
- Quarterly Accounts Payables rose 199.2% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (up 199.2% YoY) and the FY2025 annual result came in at $2.0 million, up 321.09% from the prior year.
- Accounts Payables fell to $1.1 million in Q1 2026 per MLYS's latest filing, from $2.0 million in the prior quarter.
- Over five years, Accounts Payables peaked at $5.6 million in Q3 2023 and troughed at $373000.0 in Q1 2025.
- A 5-year average of $2.1 million and a median of $2.0 million in 2022 frame the typical range for Accounts Payables.
- The widest YoY moves for Accounts Payables: up 321.09% in 2025, down 91.25% in 2025.
- Over 5 years, Accounts Payables stood at $1.9 million in 2022, then sank by 68.48% to $601000.0 in 2023, then retreated by 20.3% to $479000.0 in 2024, then soared by 321.09% to $2.0 million in 2025, then plunged by 44.67% to $1.1 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $1.1 million, $2.0 million, and $1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Mineralys Therapeutics | 2.27 Bn | 1.60 Bn | - | 1.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.07 Mn |
| Mar 31, 2026 | 1.12 Mn |
| Dec 31, 2025 | 2.02 Mn |
| Sep 30, 2025 | 1.12 Mn |
| Jun 30, 2025 | 3.16 Mn |
| Mar 31, 2025 | 373,000.00 |
| Dec 31, 2024 | 479,000.00 |
| Sep 30, 2024 | 3.11 Mn |
| Jun 30, 2024 | 1.71 Mn |
| Mar 31, 2024 | 4.26 Mn |
| Dec 31, 2023 | 601,000.00 |
| Sep 30, 2023 | 5.57 Mn |
| Jun 30, 2023 | 2.20 Mn |
| Mar 31, 2023 | 2.39 Mn |
| Dec 31, 2022 | 1.91 Mn |